Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 30
Summary
- Conditions
- Non -Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 20 years and 125 years
- Gender
- Both males and females
Description
Besides the main objective, there are 3 other objectives as follows: To evaluate the anti-cancer effect of HM61713 in NSCLC patients with EGFR mutation To investigate the pharmacokinetic profile of HM61713 and its metabolites after oral administration To investigate biomarkers related to the safety ...
Besides the main objective, there are 3 other objectives as follows: To evaluate the anti-cancer effect of HM61713 in NSCLC patients with EGFR mutation To investigate the pharmacokinetic profile of HM61713 and its metabolites after oral administration To investigate biomarkers related to the safety and efficacy of HM61713
Tracking Information
- NCT #
- NCT01588145
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Dong-Wan Kim, MD PhD Seoul National University Hospital
Get Well Soon